Purpose The ovarian cancer data set from The Cancer Genome Atlas integrates genomic and proteomic data with clinical annotations based on chart abstractions. We aimed to develop an algorithm to create a matching, more accessible clinical data set cataloging time to treatment failure (TTF) of sequential lines of treatment in patients with serous ovarian cancers.
INTRODUCTION
In 2017, 22,440 new diagnoses of ovarian cancer are projected to occur in the United States, leading to 14,480 deaths. 1 Approximately 70% of these diagnoses are high-grade serous ovarian cancers (SOCs), and 70% to 80% of patients have stage III or IV disease at diagnosis. 2 Ovarian cancers often respond dramatically to cytotoxic chemotherapies, although the majority of patients will experience relapse. 3 There is still a dearth of information regarding the longitudinal experience with chemotherapy outcomes. [4] [5] [6] The Cancer Genome Atlas (TCGA) has accrued more than 10,000 tissue samples and clinical data on 33 different tumor types, with the goal of documenting high-resolution measurements of messenger RNA expression, microRNA expression, DNA copy number, and DNA promoter methylation. 7, 8 The ovarian cancer TCGA was originally intended to focus on high-grade and high-stage SOCs. 9 Several publications have analyzed the implications of genomic alterations in SOC regarding survival and response to firstline chemotherapy. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] However, the clinical annotations in the TCGA, although rich in information, remain difficult to analyze. Limited information on clinical outcomes related to subsequent lines of chemotherapy exists within the ovarian data set. In this study, we created an algorithm to quantify the time to treatment failure (TTF) of different lines of therapy for recurrent disease, as well as different therapeutic combinations, by extrapolating from the time of starting one therapy to the time of starting a subsequent therapy. This data annotation provides the opportunity to define genomic patterns of chemotherapeutic resistance.
MATERIALS AND METHODS

Ovarian Cancer TCGA Data Set
We extracted two clinically annotated TCGA SOC data sets for this study. The master data set contains all data on 587 patients with ovarian cancer within the 2011 clinical annotation set. We created a high-risk data set to achieve a more homogeneous and clinically relevant population from which to analyze treatment and outcomes data. We included only 450 patients with grade 3 tumors and stage III ot IV disease ( Table 1) . The final, complete, reannotated master and high-risk data sets are included in the Data Supplement, along with the original patient and chemotherapy data. Data herein contain data from the high-risk data set unless otherwise specified. The clinical data cutoff for this analysis was August 9, 2011 .
Chemotherapy Annotation
Pertinent clinical information gathered in the original clinical annotation includes age at pathologic diagnosis, stage, tumor grade, days to death, days to last follow-up, days to tumor progression, days to tumor recurrence, sex, primary therapy outcome using Response Evaluation Criteria in Solid Tumors (RECIST) measures, race, and vital status. The chemotherapy annotation, however, made extraction of valuable data more difficult as a result of its complexity. The chemotherapy data included information such as days to drug start and end, drug name, and regimen indication. Infrequently, the doses for certain drugs were also included. Each patient typically had multiple lines of therapy at different time points that were difficult to readily analyze on a large scale.
Overall Survival
Overall survival (OS) is calculated as the time from diagnosis to the latest date found for any of the following: death, last follow-up, progression, recurrence, or last chemotherapy.
TTF
Because there is no documentation of progression-free survival (PFS) for each therapeutic regimen, we have inferred that the initiation of a new therapy signifies that the patient had experienced recurrence or progression of disease. TTF in the first line of therapy is calculated as the difference between the chemotherapy start date and date of relapse; time to progression, recurrence, or death; or time to last follow-up. Patients who are still disease free after first-line therapy are annotated as free and are censored. Subsequently, TTF is calculated as the difference between the start date of a numbered chemotherapy regimen and the next chemotherapy regimen start date (eg, if third-line chemotherapy started at 450 days and second-line therapy started at 150 days, then the TTF for the second-line chemotherapy regimen is 300 days). If no data exist for subsequent chemotherapy, days to death or days to last follow-up were used as the final time point. Changes in therapy still considered adjuvant in nature were not counted as events in TTF.
Chemotherapy Regimens
Chemotherapy regimens were simplified by grouping chemotherapeutic agents (both generic and trade names) into their following respective drug classes: platinum (eg, carboplatin, cisplatin, oxaliplatin), taxane (eg, paclitaxel, docetaxel, nanoparticle albumin-bound paclitaxel), doxorubicin (eg, doxorubicin, liposomal doxorubicin), topotecan, gemcitabine, or other (all other chemotherapy classes). For the full list of all chemotherapy agents administered, see Appendix Figure A1 . We cut off our data at six lines of therapy, although there were eight patients in the high-risk data set who received more than six lines, three of whom received a total of nine lines ( Table 2) .
Cumulative Clinical Benefit
Cumulative clinical benefit (CCB) incorporates the overall TTF from a class of chemotherapy administered as a single agent. It differs from TTF in that the CCB of a regimen in all lines is added together. For instance, in a single patient, if the TTF for the second-line regimen of doxorubicin is 200 days and the TTF for a fourthline regimen re-treating with doxorubicin is 400 days, then the CCB of doxorubicin in that patient equals 600 days. This represents the overall time a patient has received benefit from a particular class of agents throughout her treatment course. CCB is only calculated using an equivalent drug within the prespecified drug classes and does not include drugs used in combination with other classes of agents.
Censoring
Censoring for TTF occurs if a patient remains on a current line of therapy and has not started a new line of therapy, has died, or has experienced progression. For CCB, censoring is applied if the patient is still receiving a particular therapy at the ascopubs.org/journal/cci JCO™ Clinical Cancer Informatics 3 
Classification of Platinum Sensitivity
For this analysis, patients receiving first-line therapy who experienced progression or recurrence ≥ 6 months after their last platinum dose are considered platinum sensitive. Platinum-resistant patients experienced treatment failure from 1 to 6 months after their last platinum dose. Platinum-refractory patients experienced treatment failure during treatment or within 1 month of their last platinum dose. Patients who had not yet experienced relapse and were free of disease within 6 months of their last platinum dose were excluded from the resistant and refractory groups in this analysis. 22 Time since last platinum dose before recurrence is calculated as the difference between the last day of first-line platinum and treatment failure in patients who have experienced recurrence, progression, or death. In patients currently free of disease, the last day of platinum is subtracted from total days (OS) to obtain this value. The last day of platinum treatment in the first line of therapy is equal to days to drug therapy end for first-line chemotherapy. However, for patients for whom there was incomplete data, we estimated each cycle length to be 21 days, which was added to days to drug therapy start. If there was no information on number of cycles, we assumed six cycles were given. Patients who had not yet experienced relapse and were free of disease were excluded from the resistant and refractory groups if their follow-up time was < 6 months from their last platinum dose.
Statistical Analyses
Kaplan-Meier curves were created using Graph-Pad Prism Mac OS X version 5 (GraphPad Software, La Jolla, CA 
RESULTS
Demographic Information of the TCGA Data Set
The master TCGA ovarian cancer data set contains 587 patients. 9 The high-risk data set, composed only of patients with both grade 3 and stage III or IV disease, contains 450 patients. Of the patients in the master data set, 89.3% had stage III to IV disease at presentation, and 82.5% had grade 3 disease ( Table 1 ). The mean age was nearly identical in the high-risk data set (59.9 years; 95% CI, 58.8 to 60.9 years) and master data set (59.7 years; 95% CI, 58.8 to 60.7 years; P = .83). The available racial demographic data demonstrated a predominantly white population.
Chemotherapy Regimens and Lines of Treatment
Up to six lines of chemotherapy were annotated in both data sets ( Table 2) . Fourteen patients (2.4%) in the master data set and eight patients (1.8%) in the high-risk data set received more than six lines of therapy (not included in TTF analysis). Excluding patients for whom there is insufficient chemotherapy data, all of the patients (100%) in the high-risk data set received a platinum agent in their first line of treatment, either in combination with a taxane (86%) or other drugs (11%) or as a single agent (3%). More than 20 different chemotherapies or chemotherapy combinations were used (Appendix Fig A1) . Upon becoming platinum resistant, the second and third most common treatments of choice were doxorubicin and topotecan, used as single agents (Appendix Fig A2) .
Platinum Sensitivity Status
Patients with late recurrences after first-line treatment often remain sensitive to platinum-based chemotherapies. Figure 1A shows the OS of patients based on whether they were sensitive to platinum agents in the first line. These OS data for platinum sensitivity correlate closely with the documented RECIST responses to treatment. Figure 1B shows the OS of patients stratified based on RECIST response criteria. Patients with complete responses exhibited the highest median OS (54.1 months), whereas patients with progressive disease had a worse median OS (20.9 months). Interestingly, patients who achieved partial responses (PR) did not significantly differ in their median OS from those with stable disease (SD; 33.7 v 34.4 months, respectively; P = .95). Figure 1C illustrates TTF outcomes of first-line therapy stratified based on RECIST responses. Patients who experienced a complete response had a longer TTF (18.0 months) compared with patients who had PR and SD, whereas patients who had progressive disease had a shorter TTF (6.0 months). Again, there was no statistically significant difference in patients with PR and SD (9.1 v 13.5 months, respectively; P = .25).
TTF of Chemotherapy Based on Line of Treatment
The clinical benefit of any chemotherapy decreases with each successive line of treatment in what seems to be an asymptotic fashion. In high-risk patients, the median TTFs were 14.8, 10.2, 5.7, and 4.1 months in the first, second, third, and fourth lines, respectively. However, in patients who are still healthy enough to receive cytotoxic therapies after third-line treatment, the efficacy of chemotherapy seems to normalize, with a median TTF between 3 and 5 months ( Fig  2A) . Note that discrepancies in values listed here compared with Table 2 are a result of variations in data that were available in the TCGA cohort. Occasionally, dates were available for treatments but no drug was listed, or there were drugs listed but no treatment dates. This occurred in four patients in first line, seven patients in second line, three patients in third line, two patients in fourth line, and zero patients in fifth and sixth lines.
Choice of Chemotherapy After First-Line Treatment Failure
Once ovarian cancer had become resistant to platinum-based therapies, the four most common single-agent chemotherapies used were doxorubicin, topotecan, taxane, and gemcitabine, in descending order of frequency (Appendix Fig A1) . Figure 2B illustrates the CCB of each of these single-agent drugs in all lines of therapy. Doxorubicin exhibited a median CCB of 5.5 months, which was not statistically different than the CCB for topotecan (4.6 months), taxanes (4.2 months), or gemcitabine (6.0 months). It is important to note that many of these drugs were given in combination with platinum chemotherapies, although they were rarely repeated as single agents after combined therapy failure (Appendix Fig A1) .
The choice of which drug to give after initial recurrence or progression depends largely on whether the patient is considered to have been sensitive to the platinum-based combination given in the first-line setting. Within this data set, after primary recurrence, only 65% of patients with platinum-sensitive disease, defined as reinitiation of treatment > 6 months after the last platinum dose, were treated in the second line with a platinum-containing regimen. Of patients with platinum-resistant or platinum-refractory disease, defined as reinitiation of treatment within 6 months of the last platinum dose, 21% were subsequently placed on a platinum-containing regimen (Appendix Fig A2) . Platinum-sensitive patients re-treated in the second line with a platinum-based chemotherapy demonstrated a 2.5-month improvement in TTF and 10.4-month OS benefit compared with platinum-sensitive patients receiving non-platinum-based therapy (other; Figs 3A and 3B) . Patients considered to have platinum-resistant or platinum-refractory disease received neither quantifiable benefit nor detriment in TTF or OS when retreated with a platinum-based chemotherapy versus nonplatinum therapy (other; Figs 3C and 3D) . Figure 3E shows that the magnitude of the disease-free interval after primary therapy may influence the use of agents despite recommendations to re-treat with platinum-based chemotherapy for patients who experience relapse 6 months after their most recent chemotherapy. 23 Platinum-sensitive patients re-treated with platinum-based chemotherapy in the second line had a longer disease-free interval before the first recurrence (19.1 months; 95% CI, 15.5 to 22.7 months) than platinum-sensitive patients who received a non-platinum-based (other) therapy (13.5 months; 95% CI, 10.8 to 16.2 months; P = .038; Figs 3E and 3F). Of patients who experienced recurrence within 6 to 12 months, only 48% received doublet therapy, whereas 68% of patients who experienced recurrence after 12 months of their last dose received doublet therapy (data not shown). Platinum-based chemotherapeutic agents often remained effective in platinum-sensitive patients, even through later lines of therapy (Appendix Fig A3A) . The TTFs of patients receiving single-agent doxorubicin versus topotecan were not appreciably different when comparing similar lines of therapy (Appendix Figs A3B and A3C).
Effect of BRCA Mutations on TTF in Different Lines of Treatment
As has been previously reported, mutations in BRCA1 and/or BRCA2 are strongly associated with better overall responses and prognosis in patients with ovarian cancer. 10, [24] [25] [26] [27] High-risk patients with BRCA1/2 mutations had a median OS of 66.6 months, whereas patients with wildtype BRCA had a median OS of 38.1 months (hazard ratio [HR], 0.52; 95% CI, 0.4 to 0.71; P < .001; Fig 4) . Patients harboring BRCA1/2 mutations derived more clinical benefit compared with wild-type patients in both the first line (HR, 0.65; 95% CI, 0.5 to 0.85; P = .001] and second line of therapy (HR, 0.64; 95% CI, 0.44 to 0.94; P = .021; Fig 4B) . By the third line of therapy, and beyond, this benefit was not as pronounced (HR; 0.76; 95% CI, 0.54 to 0.99; P = .076); however, this may be limited by the relatively small numbers in the analysis (Appendix Figs A4 and A5) .
DISCUSSION
This work represents a top-to-bottom reorganization and analysis of the TCGA ovarian cancer chemotherapy data set, previously limited primarily to first-line outcomes. We are now able to learn more about how patients respond to subsequent lines and types of chemotherapy, increasing our capabilities to query the genetic and epigenetic changes associated with such differences. Our study may also act as a baseline for historical controls for different lines of therapy, different classes of chemotherapy agents, and effects of BRCA mutations to supplement other literature. [28] [29] [30] One of the primary caveats of using a surrogate, such as TTF, instead of a validated end point, such as PFS, in later lines of therapy is a potential overestimation of TTF for the final line of chemotherapy because patients are often off all chemotherapy for variable amounts of time before death. In addition, using TTF as opposed to PFS may underestimate the efficacy of drugs in earlier lines of therapy because some patients may have had changes to therapy based on toxicity.
Unfortunately, we are unable to make this distinction within the confines of this data set.
These new data may allow us to better manage our expectations during clinical drug development in SOC. As expected, TTF decreases substantially after each subsequent line of therapy. The differences in the first four lines of therapy were all statistically significant; however, the TTF of later lines of therapy did not show clinically or statistically significant differences, with the median TTF of most drugs normalizing to approximately 3 to 5 months after third-line therapies.
The results from the later lines of therapy may be limited as a result of the small number in those groups. Treating patients on clinical trials who have had multiple prior lines of chemotherapy may underestimate the potential efficacy of drug targets unless a good historical precedent for the line of therapy is considered. 31 Of note, the choice and sequencing of non-platinum-based therapy do not seem to be significant indicators of OS because they all exhibit similar efficacy with nearly equal CCB despite being given in different lines of therapy.
This work also confirms the well-known importance of the use of platinum-based chemotherapy in ovarian cancer. Platinum-sensitive patients who did not receive platinum therapies in the second line had inferior OS and TTF compared with their counterparts who received a platinum drug in the second line. This matches data from a randomized controlled trial in which nonplatinum versus platinum-based chemotherapy was used in patients who experienced recurrence within 6 to 12 months of their last platinum therapy to try to increase platinum-free interval. Delay of platinum chemotherapy led to worse OS compared with standard-of-care therapy. 32
Finally, this data set demonstrates the sensitivity to DNA-damaging agents in patients who harbor BRCA mutations, as has been shown in prior studies. 25, 33 These patients had significant increases in TTF and OS compared with patients with wild-type BRCA. However, TTF in these patients normalized after the third line of treatment, suggesting resistance mechanisms similar to other ovarian cancers.
The ovarian TCGA data set provides unique opportunities to evaluate responsiveness to downstream therapies compared with other cancer types within the TCGA. It is our hope that this reannotation improves the ability of biostatisticians to analyze potential genetic signatures of sensitivity and resistance for different drug types in this large cohort of patients. Patients with three to six lines of chemotherapy were combined on the basis of prior research that shows that the data are similar in these groups; this also explains the larger number of patients in this group.
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